AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Dartmouth researchers expose weakness of common parasite.(Brief Article)

Vaccine Weekly

| April 17, 2002 | COPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2002 APR 17 - (NewsRx.com & NewsRx.net) -- Dartmouth Medical School geneticists in the Department of Microbiology and Immunology have discovered how to weaken a common human parasite to prevent disease in an animal model after infection by the normal parasite.

The work, reported in the journal Nature (Feb. 2002), opens new avenues for the development of vaccines and other treatments for diseases such as toxoplasmosis caused by a diverse, but related group of protozoan parasites.

Barbara A. Fox, a research associate, and David J. Bzik, PhD, associate professor of microbiology and immunology, found that inactivating a single enzyme in a key biochemical pathway prevented Toxoplasma gondii from causing disease.

The T. gondii parasite, most commonly spread through undercooked meat (and occasionally through cats), causes toxoplasmosis, which generally poses no problems in infected people, but can be life threatening in immunocompromised patients and cause severe birth defects in newborns from primary infections during pregnancy. T. gondii belongs to a family of parasites that include the human pathogens Cryptosporidium parvum, also a danger for immunocompromised patients, and Plasmodium falciparum, a cause of virulent malaria that kills more than 2 million children worldwide each year.

Fox and Bzik have devised a mutant T. gondii strain that causes no disease and, more importantly, provides protection against the normal parasite. "Because of the extraordinary ability of this mutant parasite to infect the animal host without apparent ill effects, this mutant could be used as a prototype vaccine strain," said Bzik.

"This parasite is amenable to further genetic manipulation; it has an amazing ability to elicit a strong immune response that is likely to be beneficial for certain vaccines targeted against other challenging infectious diseases or cancer," added Fox.

"Parasites have been around a long time and have become very proficient at stealing things from their host, if they can. This parasite seemed to rely on just one pathway for obtaining some of the key components of its genetic material. Most other organisms have retained two functional pathways: they can make components new (de novo), or they can salvage them from their nutrient environment, " Bzik explained.

Related articles from newspapers, magazines, journals, and more
De Novo Pharmaceuticals Ltd Announces a Major Initiative to Develop a...
Press release article from: PR Newswire February 4, 2002 700+ words
CAMBRIDGE, UK and LONDON -- De Novo Pharmaceuticals (De Novo) and Sun Microsystems (TM) have today announced a joint...develop a comprehensive chemoinformatics platform. De Novo and SUN will pool their resources to co-develop a comprehensive...
De Novo Pharmaceuticals Ltd Announces a Major Initiative to Develop a...
Press release article from: PR Newswire October 16, 2001 700+ words
...United Kingdom, Oct. 16 /PRNewswire/ -- De Novo Pharmaceuticals Ltd, Cambridge, UK, ("De Novo") announced today that they have entered...development collaboration with Roche in the area of de novo drug design. Under the terms of the agreement...
De novo bank exit.
Magazine article from: Journal of Money, Credit & Banking DeYoung, Robert October 1, 2003 700+ words
...recent research indicates that these "de novo" banks tend to locate in post-merger...1990s. The long-run probability of de novo bank exit (by failure, acquisition...used to construct hazard functions for de novo failure, acquisition, and conversion...
De Novo Pharmaceuticals and Peakdale Molecular Announce Strategic Alliance.
Press release article from: PR Newswire April 1, 2003 700+ words
...CAMBRIDGE, UK, April 1 /PRNewswire/ -- De Novo Pharmaceuticals (De Novo) and Peakdale Molecular (Peakdale) announced...skills in molecular design and chemistry synthesis. De Novo has world-leading proprietary expertise for the...
De Novo Pharmaceuticals Ltd and Roche Announce the Successful Creation of a...
Press release article from: PR Newswire February 17, 2003 700+ words
...CAMBRIDGE, UK, Feb. 17 /PRNewswire/ -- De Novo Pharmaceuticals Ltd (Cambridge, UK) (De Novo) and Roche announced today the successful...the two pre-eminent groups in the world of de novo drug design, in order to build upon SkelGen...
De Novo Pharmaceuticals Ltd and ChemOvation Ltd Announce Drug Research...
Press release article from: PR Newswire October 31, 2001 700+ words
CAMBRIDGE, UK, Oct. 31 /PRNewswire/ -- De Novo Pharmaceuticals Ltd (De Novo) and ChemOvation Ltd are pleased to announce...synthetic chemistry services directed towards certain De Novo drug discovery targets. Under the terms of the...
De Novo Pharmaceuticals Ltd Announces Drug Design and Discovery Partnership...
Press release article from: PR Newswire March 9, 2001 700+ words
CAMBRIDGE, UK, March 9 /PRNewswire/ -- De Novo Pharmaceuticals Ltd (Cambridge, UK) (De Novo) announced today that it has entered a collaboration with Organon under De Novo's Drug Design Partnership Program. Under the terms...
De Novo Ventures Takes the Lead in a Series of Medical Device Investments; New...
Press release article from: Business Wire June 8, 2004 700+ words
...BUSINESS WIRE)--June 8, 2004 De Novo Ventures today announced its first seven investments from its second fund, De Novo Ventures II, which initially closed in...to significant, unmet clinical needs. De Novo most recently co-led an $18.4 million...
De Novo Pharmaceuticals Limited Announces Deployment of Integrated Drug Design...
Press release article from: PR Newswire April 4, 2001 700+ words
...CAMBRIDGE, UK, April 4 /PRNewswire/ -- De Novo Pharmaceuticals Ltd, Cambridge, UK, ("De Novo"), an emerging computational drug design...Dean (CSO) as Executive Directors on the De Novo Board. Dr. David Bailey, Chief Executive...
Argenta Discovery and De Novo Pharmaceuticals to Collaborate.
Press release article from: PR Newswire October 31, 2001 700+ words
...Argenta Discovery Limited (Harlow, UK) and De Novo Pharmaceuticals Limited (De Novo) (Cambridge, UK) have entered into a collaborative agreement directed towards certain De Novo drug discovery targets. Argenta will provide...
For more facts and information, see all results

Source: HighBeam Research, Dartmouth researchers expose weakness of common parasite.(Brief...

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA